Risk Factors for Post-ESWL and Post-ERCP Pancreatitis
1 other identifier
observational
714
0 countries
N/A
Brief Summary
The study aimed to identify risk factors for post-ERCP pancreatitis(PEP) after ESWL, and the relationship between the occurrence of post-ESWL pancreatitis and PEP.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2016
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 31, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
July 31, 2019
CompletedFirst Submitted
Initial submission to the registry
November 3, 2020
CompletedFirst Posted
Study publicly available on registry
November 6, 2020
CompletedNovember 6, 2020
November 1, 2020
2.7 years
November 3, 2020
November 3, 2020
Conditions
Outcome Measures
Primary Outcomes (2)
post endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis
The main outcome analyzed was the development of post-procedural pancreatitis, which was defined as clinical pancreatitis, meeting two of three the following criteria in accordance with the Revised Atlanta International consensus including pain consistent with AP; amylase or lipase more than 3 times the upper normal limit; characteristic findings on imaging.
up to 1 months
post pancreatic extracorporeal shock wave lithotripsy (ESWL) pancreatitis
The main outcome analyzed was the development of post-procedural pancreatitis, which was defined as clinical pancreatitis, meeting two of three the following criteria in accordance with the Revised Atlanta International consensus including pain consistent with AP; amylase or lipase more than 3 times the upper normal limit; characteristic findings on imaging.
up to 1 months
Eligibility Criteria
Consecutive CP patients treated with both ESWL and subsequent ERCP during the same hospitalization between October 2016 and July 2019 were included.
You may qualify if:
- Patients diagnosed with chronic pancreatitis and treated with both ESWL and subsequent ERCP
You may not qualify if:
- Patients with isolated pancreatic tail stone
- Patients with suspected or established malignancy
- Patients with pancreatic ascites
- Patients attending other interventional clinical trials
- Patients with non-correctable coagulation disorder
- Patients with pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Ru N, Qian YY, Zhu JH, Chen H, Zou WB, Hu LH, Pan J, Guo JY, Li ZS, Liao Z. Post-ESWL and post-ERCP pancreatitis in patients with chronic pancreatitis: Do they share the same risks? J Hepatobiliary Pancreat Sci. 2021 Sep;28(9):778-787. doi: 10.1002/jhbp.1013. Epub 2021 Jul 22.
PMID: 34242478DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
November 3, 2020
First Posted
November 6, 2020
Study Start
October 31, 2016
Primary Completion
July 31, 2019
Study Completion
July 31, 2019
Last Updated
November 6, 2020
Record last verified: 2020-11